Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1280706rdf:typepubmed:Citationlld:pubmed
pubmed-article:1280706lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:1280706lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:1280706lifeskim:mentionsumls-concept:C0234421lld:lifeskim
pubmed-article:1280706lifeskim:mentionsumls-concept:C0019010lld:lifeskim
pubmed-article:1280706lifeskim:mentionsumls-concept:C0075193lld:lifeskim
pubmed-article:1280706lifeskim:mentionsumls-concept:C1449702lld:lifeskim
pubmed-article:1280706lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1280706pubmed:issue4lld:pubmed
pubmed-article:1280706pubmed:dateCreated1993-1-7lld:pubmed
pubmed-article:1280706pubmed:abstractTextTo evaluate the pattern of hemodynamic responses produced by an inhibitor of protein kinase C (PKC), staurosporine 0.03-0.55 mg/kg was administered intravenously (i.v.) to conscious, normotensive rats chronically instrumented with vascular catheters for direct measurement of blood pressure (BP) and i.v. administration of drugs and either an aortic flow probe for measurement of cardiac output (CO) or miniaturized pulsed Doppler flow probes for measurement of hindquarter, renal, and mesenteric vascular resistances. Staurosporine decreased mean arterial pressure (MAP) and total peripheral resistance (TPR) and increased heart rate (HR) in a dose-dependent manner. Because staurosporine decreased resistance in all three vascular beds monitored (hindquarter, renal, and mesenteric), staurosporine is probably a nonselective vasodilator that decreases MAP by decreasing resistance in a number of peripheral vascular beds. Staurosporine produced biphasic effects on CO, dF/dtmax and peak aortic blood flow; these parameters were significantly increased at doses less than 0.3 mg/kg and decreased to levels equal to or significantly less than control values at doses greater than 0.3 mg/kg. In comparison, the calcium channel blocker nitrendipine decreased MAP and TPR and increased HR, CO, dF/dtmax, and peak aortic flow in a dose-dependent manner over the entire dose range (0.01-1 mg/kg i.v.). Staurosporine (0.3 mg/kg) and nitrendipine (1 mg/kg) produced similar changes in MAP (-44 +/- 3 and -33 +/- 2 mm Hg, respectively), yet staurosporine affected dF/dtmax to a lesser extent than nitrendipine (-5 +/- 36 and 390 +/- 46 ml/s/s, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1280706pubmed:languageenglld:pubmed
pubmed-article:1280706pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280706pubmed:citationSubsetIMlld:pubmed
pubmed-article:1280706pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280706pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280706pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280706pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280706pubmed:statusMEDLINElld:pubmed
pubmed-article:1280706pubmed:monthOctlld:pubmed
pubmed-article:1280706pubmed:issn0160-2446lld:pubmed
pubmed-article:1280706pubmed:authorpubmed-author:SilverP JPJlld:pubmed
pubmed-article:1280706pubmed:authorpubmed-author:BuchholzR ARAlld:pubmed
pubmed-article:1280706pubmed:authorpubmed-author:PrattP FPFlld:pubmed
pubmed-article:1280706pubmed:authorpubmed-author:ChanH PHPlld:pubmed
pubmed-article:1280706pubmed:authorpubmed-author:BrousseauA...lld:pubmed
pubmed-article:1280706pubmed:authorpubmed-author:DundoreR LRLlld:pubmed
pubmed-article:1280706pubmed:authorpubmed-author:HabeebP GPGlld:pubmed
pubmed-article:1280706pubmed:authorpubmed-author:BeckerL TLTlld:pubmed
pubmed-article:1280706pubmed:issnTypePrintlld:pubmed
pubmed-article:1280706pubmed:volume20lld:pubmed
pubmed-article:1280706pubmed:ownerNLMlld:pubmed
pubmed-article:1280706pubmed:authorsCompleteYlld:pubmed
pubmed-article:1280706pubmed:pagination525-32lld:pubmed
pubmed-article:1280706pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:meshHeadingpubmed-meshheading:1280706-...lld:pubmed
pubmed-article:1280706pubmed:year1992lld:pubmed
pubmed-article:1280706pubmed:articleTitleHemodynamic and renal effects of the protein kinase inhibitor staurosporine in conscious rats.lld:pubmed
pubmed-article:1280706pubmed:affiliationDepartment of Cardiovascular Pharmacology, Sterling Winthrop Pharmaceuticals Research Division, Rensselaer, New York 12144.lld:pubmed
pubmed-article:1280706pubmed:publicationTypeJournal Articlelld:pubmed